Drug Profile


Alternative Names: 14 839JL; JL 14839

Latest Information Update: 14 Oct 1997

Price : $50

At a glance

  • Originator Logeais
  • Class Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 14 Oct 1997 Discontinued-Unspecified for Parkinson's disease in Italy (PO)
  • 14 Oct 1997 Discontinued-Unspecified for Parkinson's disease in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top